Latest Sernova Corp (SEOVF) Headlines
Sernova Announces Annual Meeting, Record Date and Adopts Advance Notice By-Law
Marketwire - Wed Feb 26, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and haemophilia is pleased to announce that it will hold an annual general and special meeting of shareholders (the "AGM") on April 28, 2014. The record date for shareholders entitled to vote at the AGM is March 24, 2014.
Frank Holler Joins Sernova's Board of Directors
Marketwire - Tue Feb 11, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, today announced the appointment of Mr. Frank Holler to its Board of Directors. A Vancouver-based entrepreneur and investor, Holler brings 25 years of success-driven experience in the biopharma and technology sectors to Sernova's board. He has been directly involved in the founding and development of some of Canada's most successful biopharma companies including ID Biomedical, Angiotech Pharmaceuticals and Xenon Pharmaceuticals.
Fission 3 Grants Stock Options
Marketwire - Fri Jan 31, 2:46PM CST
FISSION 3.0 CORP. ("Fission 3") (TSX VENTURE: FUU) announces that it has granted incentive stock options to Directors, Officers, employees and consultants entitling them to purchase up to 14,000,000 shares in the capital of the Company subject to the policies of the TSX Venture Exchange. The options are exercisable until January 31, 2019 at a price of $0.155 per share.
Sernova Announces Appointment of Cathy Steiner as CFO
Marketwire - Fri Jan 31, 5:01AM CST
Sernova Corp (TSX VENTURE: SVA) today announced that Ms. Cathy R. Steiner, CPA CA MSc MBA has joined the Company as Chief Financial Officer.
Financial Press: Sernova's Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs
ACCESSWIRE - Wed Jan 22, 8:00AM CST
(Financial Press - Jan 22, 2014) - Imagine you are a person with diabetes who must focus on measuring your blood sugar levels almost constantly followed by injection of insulin multiple times each day or monitoring your insulin pump delivery to keep your diabetes under control. And yet, to make matters worse, you still have the potential to develop the serious long-term complications of diabetes, such as cardiovascular disease, blindness, and amputations. And, for the approximately 30% of people with Type 1 diabetes who have hypoglycemia unawareness, every insulin injection has the potential to severely drop your blood sugar levels to dangerous levels without you being aware.
Sernova's Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs
PRWeb - Wed Jan 22, 7:37AM CST
Imagine there is a person with diabetes who must focus on measuring their blood sugar levels almost constantly followed by injection of insulin multiple times each day or monitoring their insulin pump delivery to keep their diabetes under control. And yet, to make matters worse, they still have the potential to develop the serious long-term complications of diabetes, such as cardiovascular disease, blindness, and amputations. And, for the approximately 30% of people with Type 1 diabetes who have hypoglycemia unawareness, every insulin injection has the potential to severely drop their blood sugar levels to dangerous levels without being aware.
Sernova to Present Company and Clinical Update at Biotech Showcase(TM) Healthcare Conference in San Francisco
Marketwire - Mon Jan 13, 5:01AM CST
Sernova Corp (TSX VENTURE: SVA), today announced that Dr. Philip Toleikis, Ph.D., the company's Chief Executive Officer will present an update on the company's business strategy and clinical study at the Biotech Showcase(TM) healthcare conference in San Francisco, CA. This important conference brings together global industry leaders, emerging companies and members of the investment community. Sernova is currently conducting a Phase I/II clinical trial of its Cell Pouch(TM) at the University of Alberta in patients with Type 1 diabetes who are receiving an islet transplant with Dr. James Shapiro as principal investigator.
Sernova Corp Engages Carson Seabolt and Network IR
Marketwire - Wed Nov 27, 5:01AM CST
Sernova Corp (TSX VENTURE: SVA) today is pleased to announce it has engaged Carson Seabolt and Network IR ("Network") to develop and execute a comprehensive investor communications program to raise awareness of the Company within North American and International investment communities.
Sernova Corp Engages Ray Matthews & Associates
Marketwire - Wed Sep 11, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA), is pleased to announce that it is has engaged Ray Matthews & Associates Inc. ('RM&A') to provide capital markets and advisory services, including investor relations activities.
Sernova and Medicyte to Collaborate on Cell-Based Therapy to Treat Haemophilia
Marketwire - Tue Sep 10, 5:00AM CDT
Sernova Corp. (TSX VENTURE: SVA) and Medicyte GmbH, today announced that the companies have entered into a Material Transfer Agreement (MTA) to jointly evaluate the use of Medicyte's upcyte(R) cells in Sernova's Cell Pouch(TM) for the treatment of patients with haemophilia A.
Sernova to Present at 15th Annual Rodman & Renshaw Global Investment Conference
Marketwire - Wed Sep 04, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA) today announced that Dr. Philip Toleikis, Sernova's President and CEO, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, at 12:30 p.m. EDT, Tuesday, Sept. 10, in room 7.03 at the Millennium Broadway Hotel in New York City.
Sernova Announces Annual Meeting, Record Date and Adopts Advance Notice By-Law
Marketwire - Wed Feb 26, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and haemophilia is pleased to announce that it will hold an annual general and special meeting of shareholders (the "AGM") on April 28, 2014. The record date for shareholders entitled to vote at the AGM is March 24, 2014.
Frank Holler Joins Sernova's Board of Directors
Marketwire - Tue Feb 11, 5:01AM CST
Sernova Corp. (TSX VENTURE: SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes, blood disorders such as haemophilia and other diseases, today announced the appointment of Mr. Frank Holler to its Board of Directors. A Vancouver-based entrepreneur and investor, Holler brings 25 years of success-driven experience in the biopharma and technology sectors to Sernova's board. He has been directly involved in the founding and development of some of Canada's most successful biopharma companies including ID Biomedical, Angiotech Pharmaceuticals and Xenon Pharmaceuticals.
Fission 3 Grants Stock Options
Marketwire - Fri Jan 31, 2:46PM CST
FISSION 3.0 CORP. ("Fission 3") (TSX VENTURE: FUU) announces that it has granted incentive stock options to Directors, Officers, employees and consultants entitling them to purchase up to 14,000,000 shares in the capital of the Company subject to the policies of the TSX Venture Exchange. The options are exercisable until January 31, 2019 at a price of $0.155 per share.
Sernova Announces Appointment of Cathy Steiner as CFO
Marketwire - Fri Jan 31, 5:01AM CST
Sernova Corp (TSX VENTURE: SVA) today announced that Ms. Cathy R. Steiner, CPA CA MSc MBA has joined the Company as Chief Financial Officer.
Financial Press: Sernova's Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs
ACCESSWIRE - Wed Jan 22, 8:00AM CST
(Financial Press - Jan 22, 2014) - Imagine you are a person with diabetes who must focus on measuring your blood sugar levels almost constantly followed by injection of insulin multiple times each day or monitoring your insulin pump delivery to keep your diabetes under control. And yet, to make matters worse, you still have the potential to develop the serious long-term complications of diabetes, such as cardiovascular disease, blindness, and amputations. And, for the approximately 30% of people with Type 1 diabetes who have hypoglycemia unawareness, every insulin injection has the potential to severely drop your blood sugar levels to dangerous levels without you being aware.
Sernova's Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs
PRWeb - Wed Jan 22, 7:37AM CST
Imagine there is a person with diabetes who must focus on measuring their blood sugar levels almost constantly followed by injection of insulin multiple times each day or monitoring their insulin pump delivery to keep their diabetes under control. And yet, to make matters worse, they still have the potential to develop the serious long-term complications of diabetes, such as cardiovascular disease, blindness, and amputations. And, for the approximately 30% of people with Type 1 diabetes who have hypoglycemia unawareness, every insulin injection has the potential to severely drop their blood sugar levels to dangerous levels without being aware.
Sernova to Present Company and Clinical Update at Biotech Showcase(TM) Healthcare Conference in San Francisco
Marketwire - Mon Jan 13, 5:01AM CST
Sernova Corp (TSX VENTURE: SVA), today announced that Dr. Philip Toleikis, Ph.D., the company's Chief Executive Officer will present an update on the company's business strategy and clinical study at the Biotech Showcase(TM) healthcare conference in San Francisco, CA. This important conference brings together global industry leaders, emerging companies and members of the investment community. Sernova is currently conducting a Phase I/II clinical trial of its Cell Pouch(TM) at the University of Alberta in patients with Type 1 diabetes who are receiving an islet transplant with Dr. James Shapiro as principal investigator.
Sernova Corp Engages Carson Seabolt and Network IR
Marketwire - Wed Nov 27, 5:01AM CST
Sernova Corp (TSX VENTURE: SVA) today is pleased to announce it has engaged Carson Seabolt and Network IR ("Network") to develop and execute a comprehensive investor communications program to raise awareness of the Company within North American and International investment communities.
Sernova Corp Engages Ray Matthews & Associates
Marketwire - Wed Sep 11, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA), is pleased to announce that it is has engaged Ray Matthews & Associates Inc. ('RM&A') to provide capital markets and advisory services, including investor relations activities.
Sernova and Medicyte to Collaborate on Cell-Based Therapy to Treat Haemophilia
Marketwire - Tue Sep 10, 5:00AM CDT
Sernova Corp. (TSX VENTURE: SVA) and Medicyte GmbH, today announced that the companies have entered into a Material Transfer Agreement (MTA) to jointly evaluate the use of Medicyte's upcyte(R) cells in Sernova's Cell Pouch(TM) for the treatment of patients with haemophilia A.
Sernova to Present at 15th Annual Rodman & Renshaw Global Investment Conference
Marketwire - Wed Sep 04, 5:01AM CDT
Sernova Corp. (TSX VENTURE: SVA) today announced that Dr. Philip Toleikis, Sernova's President and CEO, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, at 12:30 p.m. EDT, Tuesday, Sept. 10, in room 7.03 at the Millennium Broadway Hotel in New York City.
